Citigroup Inc. Sells 57,559 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Citigroup Inc. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 44.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 71,131 shares of the medical research company's stock after selling 57,559 shares during the quarter. Citigroup Inc.'s holdings in IQVIA were worth $16,856,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IQV. Raymond James Trust N.A. grew its position in shares of IQVIA by 2.9% in the third quarter. Raymond James Trust N.A. now owns 12,714 shares of the medical research company's stock valued at $3,013,000 after purchasing an additional 353 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of IQVIA by 38.7% during the third quarter. Eagle Asset Management Inc. now owns 12,733 shares of the medical research company's stock worth $2,791,000 after buying an additional 3,553 shares during the last quarter. Activest Wealth Management acquired a new stake in shares of IQVIA in the third quarter worth $95,000. Thompson Siegel & Walmsley LLC increased its position in IQVIA by 21.9% during the third quarter. Thompson Siegel & Walmsley LLC now owns 22,292 shares of the medical research company's stock worth $5,283,000 after acquiring an additional 4,000 shares during the period. Finally, Intech Investment Management LLC acquired a new position in IQVIA during the 3rd quarter valued at $223,000. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 0.1 %

Shares of IQV stock traded up $0.20 on Thursday, reaching $201.43. The company had a trading volume of 822,837 shares, compared to its average volume of 1,177,509. The company has a 50-day moving average of $219.50 and a 200-day moving average of $226.40. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a market cap of $36.56 billion, a PE ratio of 26.43, a PEG ratio of 2.10 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IQV. Morgan Stanley decreased their target price on IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Truist Financial dropped their price objective on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a research note on Monday, November 4th. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday. Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They issued a "buy" rating and a $276.00 price target on the stock. Finally, TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.